2025 Q4 -tulosraportti
53 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 882 | - | - | ||
| 251 | - | - | ||
| 1 014 | - | - | ||
| 103 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sitten · MuokattuToday, John Kellum received a Bywaters Prize 2026 in Yokohama, which honors outstanding contributions to the understanding of acute kidney injury (AKI). . John Kellum is co chairman at KDIGO (there are two). So when he has stated that it is time for a paradigm shift, from the previous method to the NGAL test, it carries weight with the Committee. https://www.linkedin.com/feed/update/share:7443938896410955776/?midToken=AQHNGhjUHvGgYw&midSig=2iXSj9RgG7sYg1&trk=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D&trkEmail=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D-null-jlgqwg~mpb8nv4i~py-null-null&eid=jlgqwg-mpb8nv4i-py&otpToken=MTMwNDE2ZTQxYjJmYzljMmIwMmUwZmViNDExOWVlYjU4ZWNlZDg0NTkxYWQ4YTZlN2JjNTA2NjY0YjVkNWRmMWY3ZDNkZjllNGZjZGJkODM3MDg2ZjUxMTU0ZmMxMjNjYjg5ZDQ4NjUzZTAxZTllODFjOWIzZSwxLDE%3D
·6 t sittenMan, I really hope 3D is right in his prediction. Should the opposite be the case, he will have exposed himself publicly, as it happened during the SAS crash.
·10 t sittenAnyone who wants to chime in and tell what they think will happen with the stock on Thursday the 21st? I am new to the stock world and thought it was a cheap stock to try to invest a little in without it hurting if everything collapses.·9 t sitten · MuokattuI would be surprised if the stock were to move one way or the other, because they have previously presented a preliminary report. If they were to announce something positive about KDIGO, then it will rise, (but I doubt it) You can scroll down to April 26 and 27, where I have written an explanation of why KDIGO is important for Bioporto. I can only recommend that you either buy the book, Børshandlens psykologi, by Lars Tvede, or borrow it from the library. You should probably expect that the book is lent out and/or sold out, and therefore must put yourself on a waiting list.- ·17 t sittenI don't think that the analysis from the preliminary financial statement has changed. https://www.sydinvest.dk/nyheder/bioporto-sigter-fortsat-mod-at-reducere-driftsunderskuddet·11 t sittenYes, you are right that they have sold the antibody business for approximately 67 million Danish kroner. of which approx. 62 million kr. they receive immediately and approx. 10 million which they will receive after an agreement on objectives. They have divested the business to have full focus on the NGAL test. It is no coincidence that the divestment happened at this time; it was divested because KDIGO will come with their mentioned recommendations, and because they have money to promote the NGAL test. According to the last webcast and latest article from CB. Now that we are talking about KDIGO, there has been radio silence from the committee since the hearing concluded. As long as they don't say anything, no news is good news, because then there have been no research results that have disproven that NGAL works as intended.·5 t sittenYou're missing my point: To refer to an older analysis that COULD ACTUALLY point to renewed capital requirements after 2026, and then call the situation unchanged! THAT IS BOTH WRONG AND STUPID - and then I don't need that "schooling" you respond to my original post with. I'm generally open to your analyses and points otherwise. But with this post, you potentially did more harm than good, as an investor who is pro BP. It means A LOT that BP rejects further capital increases before they become profitable. BP has announced that they have their financing in place until 2028. So you say: No, end of 2026! By referring to the analysis you refer to and saying that it is still valid! Regards. Bagerbrød
·14.5.Had a bit of difficulty figuring out the situation, so I used AI to go through things: https://chatgpt.com/s/t_6a057a2958f881919bc27073ee6b3157·15 t sittenYes, agreed, except, allegedly, that they are specifically not giving a manufacturer recommendation, but a test type recommendation. Which Bioporto can then deliver on.- ·11.5.Today is the last day regarding the hearing on AKI, and it is certain that it will not be postponed further, because otherwise they would have announced it here. https://kdigo.org/kdigo-extends-public-review-for-aki-akd-guideline-to-may-11-2026/·13.5.I admit that I have been very positive about the product NGAL test, and I still am, but I have been dissatisfied with PME's flamboyant way of being a director, which I also expressed when he was director. I have now drawn a thick line in the sand when he left BP, to focus on the management that is in place today. I am very happy with the management that is in place today, and the same applies to the board, because I believe that they are very competent to drive Bioporto forward from being a research company to a commercial company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
53 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sitten · MuokattuToday, John Kellum received a Bywaters Prize 2026 in Yokohama, which honors outstanding contributions to the understanding of acute kidney injury (AKI). . John Kellum is co chairman at KDIGO (there are two). So when he has stated that it is time for a paradigm shift, from the previous method to the NGAL test, it carries weight with the Committee. https://www.linkedin.com/feed/update/share:7443938896410955776/?midToken=AQHNGhjUHvGgYw&midSig=2iXSj9RgG7sYg1&trk=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D&trkEmail=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D-null-jlgqwg~mpb8nv4i~py-null-null&eid=jlgqwg-mpb8nv4i-py&otpToken=MTMwNDE2ZTQxYjJmYzljMmIwMmUwZmViNDExOWVlYjU4ZWNlZDg0NTkxYWQ4YTZlN2JjNTA2NjY0YjVkNWRmMWY3ZDNkZjllNGZjZGJkODM3MDg2ZjUxMTU0ZmMxMjNjYjg5ZDQ4NjUzZTAxZTllODFjOWIzZSwxLDE%3D·6 t sittenMan, I really hope 3D is right in his prediction. Should the opposite be the case, he will have exposed himself publicly, as it happened during the SAS crash.
- ·10 t sittenAnyone who wants to chime in and tell what they think will happen with the stock on Thursday the 21st? I am new to the stock world and thought it was a cheap stock to try to invest a little in without it hurting if everything collapses.·9 t sitten · MuokattuI would be surprised if the stock were to move one way or the other, because they have previously presented a preliminary report. If they were to announce something positive about KDIGO, then it will rise, (but I doubt it) You can scroll down to April 26 and 27, where I have written an explanation of why KDIGO is important for Bioporto. I can only recommend that you either buy the book, Børshandlens psykologi, by Lars Tvede, or borrow it from the library. You should probably expect that the book is lent out and/or sold out, and therefore must put yourself on a waiting list.
- ·17 t sittenI don't think that the analysis from the preliminary financial statement has changed. https://www.sydinvest.dk/nyheder/bioporto-sigter-fortsat-mod-at-reducere-driftsunderskuddet·11 t sittenYes, you are right that they have sold the antibody business for approximately 67 million Danish kroner. of which approx. 62 million kr. they receive immediately and approx. 10 million which they will receive after an agreement on objectives. They have divested the business to have full focus on the NGAL test. It is no coincidence that the divestment happened at this time; it was divested because KDIGO will come with their mentioned recommendations, and because they have money to promote the NGAL test. According to the last webcast and latest article from CB. Now that we are talking about KDIGO, there has been radio silence from the committee since the hearing concluded. As long as they don't say anything, no news is good news, because then there have been no research results that have disproven that NGAL works as intended.·5 t sittenYou're missing my point: To refer to an older analysis that COULD ACTUALLY point to renewed capital requirements after 2026, and then call the situation unchanged! THAT IS BOTH WRONG AND STUPID - and then I don't need that "schooling" you respond to my original post with. I'm generally open to your analyses and points otherwise. But with this post, you potentially did more harm than good, as an investor who is pro BP. It means A LOT that BP rejects further capital increases before they become profitable. BP has announced that they have their financing in place until 2028. So you say: No, end of 2026! By referring to the analysis you refer to and saying that it is still valid! Regards. Bagerbrød
- ·14.5.Had a bit of difficulty figuring out the situation, so I used AI to go through things: https://chatgpt.com/s/t_6a057a2958f881919bc27073ee6b3157·15 t sittenYes, agreed, except, allegedly, that they are specifically not giving a manufacturer recommendation, but a test type recommendation. Which Bioporto can then deliver on.
- ·11.5.Today is the last day regarding the hearing on AKI, and it is certain that it will not be postponed further, because otherwise they would have announced it here. https://kdigo.org/kdigo-extends-public-review-for-aki-akd-guideline-to-may-11-2026/·13.5.I admit that I have been very positive about the product NGAL test, and I still am, but I have been dissatisfied with PME's flamboyant way of being a director, which I also expressed when he was director. I have now drawn a thick line in the sand when he left BP, to focus on the management that is in place today. I am very happy with the management that is in place today, and the same applies to the board, because I believe that they are very competent to drive Bioporto forward from being a research company to a commercial company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 882 | - | - | ||
| 251 | - | - | ||
| 1 014 | - | - | ||
| 103 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
53 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sitten · MuokattuToday, John Kellum received a Bywaters Prize 2026 in Yokohama, which honors outstanding contributions to the understanding of acute kidney injury (AKI). . John Kellum is co chairman at KDIGO (there are two). So when he has stated that it is time for a paradigm shift, from the previous method to the NGAL test, it carries weight with the Committee. https://www.linkedin.com/feed/update/share:7443938896410955776/?midToken=AQHNGhjUHvGgYw&midSig=2iXSj9RgG7sYg1&trk=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D&trkEmail=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D-null-jlgqwg~mpb8nv4i~py-null-null&eid=jlgqwg-mpb8nv4i-py&otpToken=MTMwNDE2ZTQxYjJmYzljMmIwMmUwZmViNDExOWVlYjU4ZWNlZDg0NTkxYWQ4YTZlN2JjNTA2NjY0YjVkNWRmMWY3ZDNkZjllNGZjZGJkODM3MDg2ZjUxMTU0ZmMxMjNjYjg5ZDQ4NjUzZTAxZTllODFjOWIzZSwxLDE%3D·6 t sittenMan, I really hope 3D is right in his prediction. Should the opposite be the case, he will have exposed himself publicly, as it happened during the SAS crash.
- ·10 t sittenAnyone who wants to chime in and tell what they think will happen with the stock on Thursday the 21st? I am new to the stock world and thought it was a cheap stock to try to invest a little in without it hurting if everything collapses.·9 t sitten · MuokattuI would be surprised if the stock were to move one way or the other, because they have previously presented a preliminary report. If they were to announce something positive about KDIGO, then it will rise, (but I doubt it) You can scroll down to April 26 and 27, where I have written an explanation of why KDIGO is important for Bioporto. I can only recommend that you either buy the book, Børshandlens psykologi, by Lars Tvede, or borrow it from the library. You should probably expect that the book is lent out and/or sold out, and therefore must put yourself on a waiting list.
- ·17 t sittenI don't think that the analysis from the preliminary financial statement has changed. https://www.sydinvest.dk/nyheder/bioporto-sigter-fortsat-mod-at-reducere-driftsunderskuddet·11 t sittenYes, you are right that they have sold the antibody business for approximately 67 million Danish kroner. of which approx. 62 million kr. they receive immediately and approx. 10 million which they will receive after an agreement on objectives. They have divested the business to have full focus on the NGAL test. It is no coincidence that the divestment happened at this time; it was divested because KDIGO will come with their mentioned recommendations, and because they have money to promote the NGAL test. According to the last webcast and latest article from CB. Now that we are talking about KDIGO, there has been radio silence from the committee since the hearing concluded. As long as they don't say anything, no news is good news, because then there have been no research results that have disproven that NGAL works as intended.·5 t sittenYou're missing my point: To refer to an older analysis that COULD ACTUALLY point to renewed capital requirements after 2026, and then call the situation unchanged! THAT IS BOTH WRONG AND STUPID - and then I don't need that "schooling" you respond to my original post with. I'm generally open to your analyses and points otherwise. But with this post, you potentially did more harm than good, as an investor who is pro BP. It means A LOT that BP rejects further capital increases before they become profitable. BP has announced that they have their financing in place until 2028. So you say: No, end of 2026! By referring to the analysis you refer to and saying that it is still valid! Regards. Bagerbrød
- ·14.5.Had a bit of difficulty figuring out the situation, so I used AI to go through things: https://chatgpt.com/s/t_6a057a2958f881919bc27073ee6b3157·15 t sittenYes, agreed, except, allegedly, that they are specifically not giving a manufacturer recommendation, but a test type recommendation. Which Bioporto can then deliver on.
- ·11.5.Today is the last day regarding the hearing on AKI, and it is certain that it will not be postponed further, because otherwise they would have announced it here. https://kdigo.org/kdigo-extends-public-review-for-aki-akd-guideline-to-may-11-2026/·13.5.I admit that I have been very positive about the product NGAL test, and I still am, but I have been dissatisfied with PME's flamboyant way of being a director, which I also expressed when he was director. I have now drawn a thick line in the sand when he left BP, to focus on the management that is in place today. I am very happy with the management that is in place today, and the same applies to the board, because I believe that they are very competent to drive Bioporto forward from being a research company to a commercial company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 882 | - | - | ||
| 251 | - | - | ||
| 1 014 | - | - | ||
| 103 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt